InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter ...

The role of complement in cancer is complex and is dependent on the type of cancer. However, most data indicates that, if the complement system is highly engaged, it has a strong antitumour effect.

UK start-up Complement Therapeutics has raised an impressive €72 million ($79 million) in first-round financing that will be used to take a gene therapy for sight-robbing disease geographic ...